Literature DB >> 19255430

Instant immunity through chemically programmable vaccination and covalent self-assembly.

Mikhail Popkov1, Beatriz Gonzalez, Subhash C Sinha, Carlos F Barbas.   

Abstract

The ability to instantly create a state of immunity as achieved in the passive transfer of hyperimmune globulin has had a tremendous impact on public health. Unlike passive immunization, active immunization, which is the foundation of vaccinology, is an anticipatory strategy with inherent limitations. Here we show that elements of active and passive immunization can be combined to create an effective chemistry-driven approach to vaccinology. Reactive immunization was used to create a reservoir of covalent polyclonal antibodies in 3 mouse strains that were subsequently engrafted with syngeneic CT26 colon or B16F10 melanoma tumors. Upon administration of designed integrin alpha(v)beta(3) and alpha(v)beta(5) adapter ligands, the induced covalent polyclonal antibodies self-assembled with the adapter ligands and the animals mounted an instant, chemically programmed, polyclonal response against the implanted tumors. Significant therapeutic responses were observed without recourse to adjuvant therapy. The chemically programmed immune responses were driven by antibody-dependent cellular cytotoxicity and complement-directed cytotoxicity. We suggest that this type of chemistry-driven approach to vaccinology is underexplored and may provide routes to vaccines to protect against diseases that have proven intractable to biology-driven vaccine approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255430      PMCID: PMC2649956          DOI: 10.1073/pnas.0900147106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

Authors:  B P Eliceiri; D A Cheresh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

4.  Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting.

Authors:  Kannan P Naicker; Hengguang Li; Alonso Heredia; Haijing Song; Lai-Xi Wang
Journal:  Org Biomol Chem       Date:  2004-02-02       Impact factor: 3.876

5.  Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.

Authors:  R Xiang; H N Lode; T Dreier; S D Gillies; R A Reisfeld
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

6.  Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.

Authors:  Lian-Sheng Li; Christoph Rader; Masayuki Matsushita; Sanjib Das; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

7.  Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

Authors:  F Carreiras; Y Denoux; C Staedel; M Lehmann; F Sichel; P Gauduchon
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

8.  Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors.

Authors:  M Pignatelli; M R Cardillo; A Hanby; G W Stamp
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

Review 9.  Alpha-v integrins as therapeutic targets in oncology.

Authors:  Jeffrey A Nemeth; Marian T Nakada; M Trikha; Zhihui Lang; Michael S Gordon; Gordon C Jayson; Robert Corringham; Uma Prabhakar; Hugh M Davis; Robert A Beckman
Journal:  Cancer Invest       Date:  2007-10       Impact factor: 2.176

10.  Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.

Authors:  Emanuela I Sega; Yingjuan Lu; Michael Ringor; Christopher P Leamon; Philip S Low
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-12       Impact factor: 7.038

View more
  25 in total

1.  A biosynthetic strategy for re-engineering the Staphylococcus aureus cell wall with non-native small molecules.

Authors:  James W Nelson; Alexander G Chamessian; Patrick J McEnaney; Ryan P Murelli; Barbara I Kazmierczak; Barbara I Kazmiercak; David A Spiegel
Journal:  ACS Chem Biol       Date:  2010-10-05       Impact factor: 5.100

2.  Grand challenge commentary: Synthetic immunology to engineer human immunity.

Authors:  David A Spiegel
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

3.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

4.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors:  Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal:  J Am Chem Soc       Date:  2010-09-15       Impact factor: 15.419

5.  Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Authors:  Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  Chem Commun (Camb)       Date:  2013-10-25       Impact factor: 6.222

6.  Targeted instant immunity.

Authors:  Claude F Meares
Journal:  Nat Biotechnol       Date:  2009-05       Impact factor: 54.908

7.  Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Authors:  Shigehiro Asano; Julia Gavrilyuk; Dennis R Burton; Carlos F Barbas
Journal:  ACS Med Chem Lett       Date:  2014-02-13       Impact factor: 4.345

Review 8.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

9.  An antibody-recruiting small molecule that targets HIV gp120.

Authors:  Christopher G Parker; Robert A Domaoal; Karen S Anderson; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-11-18       Impact factor: 15.419

10.  Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

Authors:  Ryan P Murelli; Andrew X Zhang; Julien Michel; William L Jorgensen; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.